drugset / Trial / NCT01828476
Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer
Phase 2
Terminated
13 enrolled
Rutgers, The State University of New Jersey
AbbVie · collabNational Cancer Institute (NCI) · collabRutgers Cancer Institute of New Jersey · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the effect of combining abiraterone with medicines that may block some of the ways that cells become resistant to abiraterone. The investigators hope that these combinations of medicines will result in prostrate cancer cells dying. This study will see if overcoming diseases resistance to abiraterone will restore sensitivity to androgen deprivation therapy.
Timeline
- Start
- 2013-06
- Primary completion
- 2016-02
- Completion
- 2016-03-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abiraterone acetate | Small molecule | — | — |
| Subject | Hydroxychloroquine | Small molecule | — | — |
| Subject | Navitoclax | Small molecule | — | — |